Pharmaceutical compositions for controlled release of soluble re

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424486, 424487, 424488, 424405, 424406, 424417, 424422, 424423, 424 851, 424 854, 424 856, 4241581, 530351, 514 12, 514803, 514825, 514885, 514889, 514903, 514921, 514974, A61K 916

Patent

active

060835346

DESCRIPTION:

BRIEF SUMMARY
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is the national stage under 35 U.S. C. .sctn.371 of international application PCT/US96/03121, filed Mar. 1, 1996, and claims priority from Israeli application 112,834, filed Mar. 1, 1995.


FIELD OF THE INVENTION

The present invention relates to pharmaceutical compositions for controlled delivery of soluble forms of receptors from a polymeric matrix.


BACKGROUND OF THE INVENTION

Controlled release systems deliver a drug at a predetermined rate for a definite time period, that may range from days to years. These systems provide advantages over conventional drug therapies. For example, after ingestion or injection of standard dosage forms, the blood level of the drug rises, peaks, and then declines. Since each drug has a therapeutic range above which it is toxic and below which it is ineffective, oscillating drug levels may cause alternating periods of ineffectiveness and toxicity. In contrast, a controlled release preparation maintains the drug in the desired therapeutic range by a single administration. Other potential advantages of controlled release system include: (i) localized delivery of the drug to a particular body compartment, thereby lowering the systemic drug level; (ii) preservation of medications that are rapidly destroyed by the body (this is particularly important for biologically sensitive molecules such as proteins); (iii) reduced need for follow up care; (iv) increased comfort; and (v) improved compliance.
Optimal control of drug release may be achieved by placing the drug in a polymeric material. Polymeric materials generally release drugs by diffusion, chemical reaction, or solvent activation.
The most common release mechanism is diffusion, whereby the drug migrates from its initial position in the polymeric system to the polymer's outer surface and then to the body. Diffusion may occur through a reservoir, in which a drug core is surrounded by a polymer film, or in a matrix, where the drug is uniformly distributed through the polymeric system. Drugs can also be released by chemical reaction such as degradation of the polymer or cleavage of the drug from a polymer backbone.
Combinations of the above mechanisms are possible. Release rates from polymeric systems can be controlled by the nature of the polymeric material (for example, crystallinity or pore structure for diffusion controlled systems; the hydrolytic lability of the bonds or the hydrophobicity of the monomers for chemically controlled systems) and the design of the system (for example, thickness and shape). The advantage of having systems with different release mechanisms is that each can accomplish different goals.
For many years, controlled release systems were only capable of slowly releasing drugs of low molecular weight (<600). Large molecules, such as proteins, were not considered feasible candidates, because polypeptides were considered too large to slowly diffuse through most polymeric materials, even after swelling of the polymer. The discovery that matrices of solid hydrophobic polymers containing powdered macromolecules enabled molecules of nearly any size to be released for over 100 days permitted controlled delivery of a variety of proteins, polysaccharides, and polynucleotides. See Langer, 1990.
The proteins and polypeptides incorporated up to this date in polymeric materials for controlled release are mainly effector molecules, such as insulin, as opposed compositions for controlled release of molecules that will bind and neutralize effector molecules produced in the human body.
Tumor necrosis factor-.alpha. (TNF.alpha.) is a potent cytokine which elicits a broad spectrum of biological responses. TNF.alpha. is cytotoxic to many tumor cells and may be used in the treatment of cancer. TNF.alpha. enhances fibroblast growth and acts as a tissue remodeling agent, being thus suitable in wound healing. It further induces hemorrhagic necrosis of transplanted tumors in mice, enhances phagocytosis and cytotoxicity of polymorphonuclear neutrophils, and m

REFERENCES:
patent: 4883666 (1989-11-01), Sable et al.
patent: 4929442 (1990-05-01), Powell
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5206023 (1993-04-01), Hunziker
patent: 5324519 (1994-06-01), Dunn et al.
patent: 5470582 (1995-11-01), Supersaxo et al.
patent: 5478564 (1995-12-01), Wander et al.
patent: 5478925 (1995-12-01), Wallach et al.
R. Eliaz et al., "Long-Term Protection Against the Effects of Tumour Necrosis Factor by Controlled Delivery of the Soluble p55 TNF Receptor", Cytokine, vol. 8, No. 6, pp. 482-487, Jun., 1996.
D. Aderka et al., "Increased Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Cancer Patients" Cancer Research, vol. 51, pp. 5602-5607, Oct. 15, 1991.
D. Aderka et al., "Stabilization of the Bioactivity of Tumor Necrosis Factor by Its Soluble Receptors", J. Exp. Med., vol. 175, pp. 323-329, Feb., 1992.
H. Engelmann et al., "A Tumor Necrosis Factor-Binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity", J. Biol. Chem., vol. 264, No. 20, pp. 11974-11980, Jul. 15, 1989.
H. Engelmann et al., "Two Tumor Necrosis Factor-Binding Proteins Purified from Human Urine", J. Biol. Chem., vol. 265, No. 3, pp. 1531-1536, Jan. 25, 1990.
J.H. Korn et al., "Cloning of Genomic DNA for Tumor Necrosis Factor and Efficient Expression in CHO Cells", Lymphokine Research, vol. 7, No. 4, pp. 349-358, 1988.
R. Langer, "New Methods of Drug Delivery", Science, vol. 249, pp. 1527-1533, Sep. 28, 1990.
H. Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor", Cell, vol. 61, pp. 351-359, Apr. 20, 1990.
Y. Nophar et al., "Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the type I TNF-R, Clone Using Amino Acid Sequence Data of its Soluble Form, Encodes both the Cell Surface and a Soluble Form of the Receptor", The EMBO Journal, vol. 9, No. 10, pp. 3269-3278, 1990.
A. Oliff et al., "Tumor Secreting Human TNF/Cachectin Induce Cachexia in Mice", Cell, vol. 50, pp. 555-563, Aug. 14, 1987.
I. Olsson et al., "Isolation and Characterization of a Tumor Necrosis Factor Binding Protein From Urine", Eur. J. Haematol., vol. 42, pp. 270-275, 1989.
L. Probert et al., "Wasting, Ischemia, and Lymphoid Abnormalities in Mice Expressing T Cell-Targeted Human Tumor Necrosis Factor Transgenes", J. Immunol., vol. 151, No. 4, pp. 1894-1906, Aug. 15, 1993.
T.J. Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", Cell, vol. 61, pp. 361-370, Apr. 20, 1990.
P. Seckinger et al., "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor .alpha. Inhibitor", J. Biol. Chem., vol. 264, No. 20, pp. 11966-11973, Jul. 15, 1989.
D. Wallach, "Preparations of Lymphotoxin Induce Resistance to Their Own Cytotoxic Effect", J. Immunol., vol. 132, No. 5, May, 1984.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Pharmaceutical compositions for controlled release of soluble re does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions for controlled release of soluble re, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for controlled release of soluble re will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1483663

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.